DiaSorin rises as FDA okays new molecular diagnostic platform

Shares in Italy's DiaSorin DIAS.MI rise more than 3% after the medical diagnostics group received clearance from the U.S. Food and Drug Administration (FDA) for the first test of its new molecular diagnostic platform

The LIAISON NES platform allows the execution of molecular tests to detect several viral diseases without the need for specialized laboratory personnel with a time-to-results of 15 minutes

Equita notes the FDA approval allows the start of commercial activities for the platform, intended for use in pharmacies and urgent care centres

"With the launch of the LIAISON NES, DiaSorin further expands its molecular offering, entering for the first time in the Point of Care segment, which offers significant growth opportunities," it adds

Equita estimates the platform will provide a revenue contribution of around 10 million euros ($11.78 million) in 2026 and around 25 million euros in 2027

Shares are trading at their highest since November 5, when DiaSorin posted a Q3 miss and cut its 2025 guidance

($1 = 0.8492 euros)